Renishaw Delivers Q3 Growth Amid Strategic Adjustments and Tariff Headwinds
Renishaw has released its fiscal third-quarter results reporting continued revenue growth and reaffirming its strategic focus amid external pressures, including global tariffs and business restructuring.
Q3 Performance Surpasses Forecasts
For the three months ending March 31, 2025, Renishaw posted revenues of ÂŁ180.7 million, a 5% year-on-year increase that outpaced the 3% growth achieved in the first half of the fiscal year. The figure also represents a 7.9% sequential rise from the ÂŁ167.5 million reported in the preceding quarter, supported by what the company described as a ‘solid’ order intake.
Renishaw attributed the growth to robust demand in several key sectors. Sales of machine tool probes to consumer electronics customers saw healthy growth, and position encoders for semiconductor equipment builders also performed strongly. Meanwhile, revenues from coordinate measuring machines and gauging systems remained stable.
Nine-Month Results and Updated Forecast
For the nine months ended March 31, group revenue rose 3.8% to ÂŁ522.1 million from ÂŁ502.9 million the previous year. Pretax profit slipped slightly by 1.4% year-on-year to ÂŁ85.6 million from ÂŁ86.8 million.
As a result of recent performance, Renishaw modestly revised its annual guidance. Revenue is now expected in the range of ÂŁ700 million to ÂŁ720 million, slightly raising the lower end from the previous range of ÂŁ695 million to ÂŁ735 million. The adjusted pretax profit forecast was also refined to between ÂŁ109 million and ÂŁ127 million, from the previous ÂŁ105 million to ÂŁ135 million guidance.
Strategic Shifts and Tariff Impacts
Renishaw continues to respond proactively to a challenging external environment. A significant concern remains the impact of tariffs on exports to the U.S., which make up roughly 20% of the company’s global revenues. To mitigate the cost pressures, Renishaw is implementing surcharges where appropriate. “We continue to assess the potential global impacts of these tariffs on an ongoing basis,” the company stated.
As part of ongoing operational optimization, Renishaw confirmed it is closing the loss-making drug delivery operations within its Neurological business. This move is expected to increase group operating profit by ÂŁ3 million annually. However, exceptional closure costs of ÂŁ1.9 million were recognized in Q3, with a further ÂŁ1 million anticipated in the next six months.
Momentum Into Final Quarter
Despite the ‘volatile economic backdrop,’ Renishaw remains confident heading into the final quarter of its fiscal year. The company emphasized its ‘good momentum’ supported by steady demand across its core industrial segments. With sustained growth in high-precision metrology solutions and focused restructuring to boost profitability, Renishaw is positioning itself for a more resilient and strategically aligned future.
For more information: www.renishaw.com
